ArticleAnnals of geriatric medicine and research2026
Clinical Implications of the AWGS 2025 Sarcopenia Criteria in a Large Cohort of Community-Dwelling Thai Older Adults.
Article in Annals of geriatric medicine and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Asian Working Group for Sarcopenia (AWGS) 2025 criteria introduced revised age-specific cutoffs and appendicular skeletal muscle mass adjusted for body mass index (ASM/ BMI) as an alternative muscle mass index. We evaluated their effects on sarcopenia classification among Thai older adults.
methodsThis cross-sectional study included 8,073 community-dwelling adults aged ≥60 years attending a tertiary geriatric outpatient clinic. Low muscle mass and sarcopenia were classified using AWGS 2019 and 2025. Discordant ASM/height²- and ASM/BMIbased phenotypes were characterized, and age- and sex-adjusted associations with handgrip strength and gait speed were examined.
resultsLow muscle mass prevalence increased from 43.2% under AWGS 2019 to 44.6% after applying the revised AWGS 2025 ASM/height² cutoffs and to 51.4% after including ASM/BMI. Sarcopenia prevalence increased from 15.1% to 17.5% and 19.7%, respectively. ASM/BMI identified 547 additional participants with low muscle mass. Participants with isolated low ASM/BMI had greater overall and central adiposity than those with isolated low ASM/height². ASM/height² was positively associated with handgrip strength (standardized β=0.262, p<0.001), whereas ASM/BMI was positively associated with gait speed (standardized β=0.122, p<0.001). Neither index was consistently superior across outcomes.
conclusionAWGS 2025 broadened low muscle mass and sarcopenia classification through revised age-specific cutoffs and ASM/BMI, which identified a complementary adiposity-related phenotype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.